Argenx Se (ARGX) Receivables (2015 - 2026)
Argenx Se's (ARGX) quarterly Receivables came in at $1.9 billion in Q2 2026, down 99.84% on a YoY basis from $1197.1 billion in Q2 2025, and up 17.24% quarter-over-quarter from $1.6 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Receivables (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Receivables for 12 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables fell 99.84% year-over-year to $1.9 billion; the trailing twelve-month figure through Jun 2026 stood at $1.9 billion (down 99.84% YoY), and the FY2025 full-year result was $1.6 billion, down 99.82% from the prior year.
- Receivables improved to $1.9 billion in Q2 2026 per ARGX's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Receivables topped out at $1197.1 billion in Q2 2025 and bottomed at $112.4 million in Q2 2022.
- Historically, Receivables has averaged $133.7 billion across 5 years, with a median of $652.9 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Receivables jumped 183253.63% in 2025, then tumbled 99.84% in 2026.
- Over 5 years, Receivables stood at $275.7 million in 2022, then surged by 80.16% to $496.7 million in 2023, then surged by 82.1% to $904.5 million in 2024, then jumped by 82.1% to $1.6 billion in 2025, then grew by 17.24% to $1.9 billion in 2026.
- According to Business Quant data, Receivables over the past three periods registered $1.9 billion, $1.6 billion, and $1197.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 215.33 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 190.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Bn |
| Dec 31, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1,197.07 Bn |
| Dec 31, 2024 | 904.47 Mn |
| Jun 30, 2024 | 652.88 Mn |
| Dec 31, 2023 | 496.69 Mn |
| Jun 30, 2023 | 353.23 Mn |
| Dec 31, 2022 | 275.70 Mn |
| Jun 30, 2022 | 112.39 Mn |
| Dec 31, 2021 | 38.22 Mn |
| Jun 30, 2021 | 12.05 Mn |
| Dec 31, 2020 | 6.78 Mn |
| Jun 30, 2020 | 9.43 Mn |
| Dec 31, 2019 | 34.04 Mn |
| Jun 30, 2019 | 5.93 Mn |
| Dec 31, 2018 | 6.30 Mn |
| Jun 30, 2018 | 15.19 Mn |
| Dec 31, 2017 | 6.52 Mn |
| Jun 30, 2017 | 4.69 Mn |
| Dec 31, 2016 | 2.13 Mn |